Journal of Immunology and Allergy ’s Post

Most of the newly identified pathogenic drivers of type 2 inflammation and their corresponding treatments are related to mast cells, eosinophils, T cells, B cells, epithelial cells and sensory nerves. Epithelial barrier defects and dysbiotic microbiomes represent exciting future drug targets for chronic type 2 inflammatory conditions.  Visit our journal website for more updates: https://lnkd.in/dQ84mS8f (Source: Internet) Submissions are open for upcoming issue! Submit your manuscript to: immunologyallergy@maplejournal.com #type2inflammation #epithelialcells #inflammatory #pathogens #mastcells

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics